2021 -- S 0490 | |
======== | |
LC001547 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2021 | |
____________ | |
A N A C T | |
RELATING TO BUSINESSES AND PROFESSIONS -- PHARMACIES | |
| |
Introduced By: Senators Lawson, Quezada, Murray, Euer, Cano, Lombardi, Kallman, | |
Date Introduced: March 04, 2021 | |
Referred To: Senate Health & Human Services | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Section 5-19.1-2 of the General Laws in Chapter 5-19.1 entitled "Pharmacies" |
2 | is hereby amended to read as follows: |
3 | 5-19.1-2. Definitions. |
4 | (a) "Biological product" means a "biological product" as defined in the "Public Health |
5 | Service Act," 42 U.S.C. § 262. |
6 | (b) "Board" means the Rhode Island board of pharmacy. |
7 | (c) "Change of ownership" means: |
8 | (1) In the case of a pharmacy, manufacturer, or wholesaler that is a partnership, any change |
9 | that results in a new partner acquiring a controlling interest in the partnership; |
10 | (2) In the case of a pharmacy, manufacturer, or wholesaler that is a sole proprietorship, the |
11 | transfer of the title and property to another person; |
12 | (3) In the case of a pharmacy, manufacturer, or wholesaler that is a corporation: |
13 | (i) A sale, lease exchange, or other disposition of all, or substantially all, of the property |
14 | and assets of the corporation; or |
15 | (ii) A merger of the corporation into another corporation; or |
16 | (iii) The consolidation of two (2) or more corporations resulting in the creation of a new |
17 | corporation; or |
18 | (iv) In the case of a pharmacy, manufacturer, or wholesaler that is a business corporation, |
19 | any transfer of corporate stock that results in a new person acquiring a controlling interest in the |
| |
1 | corporation; or |
2 | (v) In the case of a pharmacy, manufacturer, or wholesaler that is a non-business |
3 | corporation, any change in membership that results in a new person acquiring a controlling vote in |
4 | the corporation. |
5 | (d) "Compounding" means the act of combining two (2) or more ingredients as a result of |
6 | a practitioner's prescription or medication order occurring in the course of professional practice |
7 | based upon the individual needs of a patient and a relationship between the practitioner, patient, |
8 | and pharmacist. Compounding does not mean the routine preparation, mixing, or assembling of |
9 | drug products that are essentially copies of a commercially available product. Compounding shall |
10 | only occur in the pharmacy where the drug or device is dispensed to the patient or caregiver and |
11 | includes the preparation of drugs or devices in anticipation of prescription orders based upon |
12 | routine, regularly observed prescribing patterns. |
13 | (e) "Controlled substance" means a drug or substance, or an immediate precursor of such |
14 | drug or substance, so designated under, or pursuant to, the provisions of chapter 28 of title 21. |
15 | (f) "Deliver" or "delivery" means the actual, constructive, or attempted transfer from one |
16 | person to another of a drug or device, whether or not there is an agency relationship. |
17 | (g) "Device" means instruments, apparatus, and contrivances, including their components, |
18 | parts, and accessories, intended: |
19 | (1) For use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or |
20 | other animals; or |
21 | (2) To affect the structure or any function of the body of humans or other animals. |
22 | (h) "Director" means the director of the Rhode Island state department of health. |
23 | (i) "Dispense" means the interpretation of a prescription or order for a drug, biological, or |
24 | device and, pursuant to that prescription or order, the proper selection, measuring, compounding, |
25 | labeling, or packaging necessary to prepare that prescription or order for delivery or administration. |
26 | (j) "Distribute" means the delivery of a drug or device other than by administering or |
27 | dispensing. |
28 | (k) "Drug" means: |
29 | (1) Articles recognized in the official United States Pharmacopoeia or the Official |
30 | Homeopathic Pharmacopoeia of the U.S.; |
31 | (2) Substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention |
32 | of disease in humans or other animals; |
33 | (3) Substances (other than food) intended to affect the structure, or any function, of the |
34 | body of humans or other animals; or |
| LC001547 - Page 2 of 7 |
1 | (4) Substances intended for use as a component of any substances specified in subsection |
2 | (k)(1), (k)(2), or (k)(3), but not including devices or their component parts or accessories. |
3 | (l) "Equivalent and interchangeable" means a drug, excluding a biological product, having |
4 | the same generic name, dosage form, and labeled potency, meeting standards of the United States |
5 | Pharmacopoeia or National Formulary, or their successors, if applicable, and not found in violation |
6 | of the requirements of the United States Food and Drug Administration, or its successor agency, or |
7 | the Rhode Island department of health. |
8 | (m) "Interchangeable biological product" means a biological product that the United States |
9 | Food and Drug Administration has: |
10 | (1) Licensed and determined meets the standards for interchangeability pursuant to 42 |
11 | U.S.C. § 262(k)(4) or lists of licensed, biological products with reference product exclusivity and |
12 | biosimilarity or interchangeability evaluations; or |
13 | (2) Determined is therapeutically equivalent as set forth in the latest edition of, or |
14 | supplement to, the United States Food and Drug Administration's Approved Drug Products with |
15 | Therapeutic Equivalence Evaluations. |
16 | (n) "Intern" means: |
17 | (1) A graduate of an American Council on Pharmaceutical Education (ACPE)-accredited |
18 | program of pharmacy; |
19 | (2) A student who is enrolled in at least the first year of a professional ACPE-accredited |
20 | program of pharmacy; or |
21 | (3) A graduate of a foreign college of pharmacy who has obtained full certification from |
22 | the FPGEC (Foreign Pharmacy Graduate Equivalency Commission) administered by the National |
23 | Association of Boards of Pharmacy. |
24 | (o) "Legend drugs" means any drugs that are required by any applicable federal or state |
25 | law or regulation to be dispensed on prescription only or are restricted to use by practitioners only. |
26 | (p) "Limited-function test" means those tests listed in the federal register under the Clinical |
27 | Laboratory Improvement Amendments of 1988 (CLIA) as waived tests. For the purposes of this |
28 | chapter, limited-function test shall include only the following: blood glucose, hemoglobin A1c, |
29 | cholesterol tests, and/or other tests that are classified as waived under CLIA and are approved by |
30 | the United States Food and Drug Administration for sale to the public without a prescription in the |
31 | form of an over-the-counter test kit. |
32 | (q) "Manufacture" means the production, preparation, propagation, compounding, or |
33 | processing of a drug or other substance or device or the packaging or repackaging. |
34 | (r) "Non-legend" or "nonprescription drugs" means any drugs that may be lawfully sold |
| LC001547 - Page 3 of 7 |
1 | without a prescription. |
2 | (s) "Person" means an individual, corporation, government, subdivision, or agency, |
3 | business trust, estate, trust, partnership, or association, or any other legal entity. |
4 | (t) "Pharmaceutical care" is the provision of drugs and other pharmaceutical services |
5 | intended to achieve outcomes related to cure or prevention of a disease, elimination or reduction of |
6 | a patient's symptoms, or arresting or slowing of a disease process. "Pharmaceutical care" includes |
7 | the judgment of a pharmacist in dispensing an equivalent and interchangeable drug or device in |
8 | response to a prescription after appropriate communication with the prescriber and the patient. |
9 | (u) "Pharmacist in charge" means a pharmacist licensed in this state as designated by the |
10 | owner as the person responsible for the operation of a pharmacy in conformance with all laws and |
11 | regulations pertinent to the practice of pharmacy and who is personally in full and actual charge of |
12 | such pharmacy and personnel. |
13 | (v) "Pharmacy" means that portion or part of a premise where prescriptions are |
14 | compounded and dispensed, including that portion utilized for the storage of prescription or legend |
15 | drugs. |
16 | (w) "Pharmacy technician" means an individual who meets minimum qualifications |
17 | established by the board, that are less than those established by this chapter as necessary for |
18 | licensing as a pharmacist, and who works under the direction and supervision of a licensed |
19 | pharmacist. |
20 | (x) "Practice of pharmacy" means the interpretation, evaluation, and implementation of |
21 | medical orders; the dispensing of prescription drug orders; participation in drug and device |
22 | selection; the compounding of prescription drugs; drug regimen reviews and drug or drug-related |
23 | research; the administration of adult immunizations pursuant to a valid prescription or physician- |
24 | approved protocol and in accordance with regulations, to include training requirements as |
25 | promulgated by the department of health; the administration of all forms of influenza |
26 | immunizations to individuals between the ages of nine (9) years and eighteen (18) years, inclusive, |
27 | pursuant to a valid prescription or prescriber-approved protocol, in accordance with the provisions |
28 | of § 5-19.1-31 and in accordance with regulations, to include necessary training requirements |
29 | specific to the administration of influenza immunizations to individuals between the ages of nine |
30 | (9) years and eighteen (18) years, inclusive, as promulgated by the department of health; provision |
31 | of patient counseling and the provision of those acts or services necessary to provide |
32 | pharmaceutical care; the responsibility for the supervision for compounding and labeling of drugs |
33 | and devices (except labeling by a manufacturer, repackager, or distributor of nonprescription drugs |
34 | and commercially packaged legend drugs and devices), proper and safe storage of drugs and |
| LC001547 - Page 4 of 7 |
1 | devices, and maintenance of proper records for them; and the performance of clinical laboratory |
2 | tests, provided such testing is limited to limited-function tests as defined herein; the authority to |
3 | prescribe drugs and devices in accordance with regulations adopted by the board of pharmacy under |
4 | § 5-19.1-34. Nothing in this definition shall be construed to limit or otherwise affect the scope of |
5 | practice of any other profession. |
6 | (y) "Practitioner" means a physician, dentist, veterinarian, nurse, or other person duly |
7 | authorized by law in the state in which they practice to prescribe drugs. |
8 | (z) "Preceptor" means a pharmacist registered to engage in the practice of pharmacy in this |
9 | state who has the responsibility for training interns. |
10 | (aa) "Prescription" means an order for drugs or devices issued by the practitioner duly |
11 | authorized by law in the state in which he or she practices to prescribe drugs or devices in the course |
12 | of his or her professional practice for a legitimate medical purpose. |
13 | (bb) "Wholesaler" means a person who buys drugs or devices for resale and distribution to |
14 | corporations, individuals, or entities other than consumers. |
15 | SECTION 2. Chapter 5-19.1 of the General Laws entitled "Pharmacies" is hereby amended |
16 | by adding thereto the following section: |
17 | 5-19.1-36. Pharmacist prescriptive authority. |
18 | (a) The department of health shall adopt regulations governing a pharmacist’s authority to |
19 | prescribe drugs and devices. The regulations for a pharmacist prescribing shall include the |
20 | conditions for which a pharmacist may prescribe an indicated drug or device. |
21 | (b) Pharmacist prescriptive authority shall be limited to conditions for which one of the |
22 | following applies: |
23 | (1) The condition does not require a new diagnosis; |
24 | (2) The condition is minor and generally self-limiting; |
25 | (3) Diagnosis of the condition or other clinical decision-making can be guided by a test |
26 | that has received a waiver under the Clinical Laboratory Improvement Amendments of 1988, 42 |
27 | U.S.C. § 263(a); or |
28 | (4) In the professional judgment of the pharmacist, immediate dispensing of a drug or |
29 | device is necessary to avoid significant harm to the patient’s health and safety. |
30 | (c) When prescribing a drug to treat a condition described in subsection (b)(4) of this |
31 | section, a pharmacist may prescribe the drug only in an amount necessary to address the condition |
32 | until the patient can be seen by another health care professional. |
| LC001547 - Page 5 of 7 |
1 | SECTION 3. This act shall take effect upon passage. |
======== | |
LC001547 | |
======== | |
| LC001547 - Page 6 of 7 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO BUSINESSES AND PROFESSIONS -- PHARMACIES | |
*** | |
1 | This act would amend the definition of the practice of pharmacy to include the authority to |
2 | prescribe drugs and devices. The act would also provide the conditions for which a pharmacist may |
3 | prescribe an indicated drug or device. |
4 | This act would take effect upon passage. |
======== | |
LC001547 | |
======== | |
| LC001547 - Page 7 of 7 |